SCHEMBL5457693

SCHEMBL5457693

NC(=O)c1c(NC(=O)N2CCOCC2)sc2c1CCOC2

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.60
NOD1 Q9Y239 1/20 0.60
CFTR P13569 1/20 0.57
CNR2 P34972 14/20 0.57
CNR1 P21554 6/20 0.56
ALDH1A1 P00352 3/20 0.53
HSD17B10 Q99714 2/20 0.53
KDM4E B2RXH2 1/20 0.53
ALOX15 P16050 1/20 0.53
PTPRC P08575 1/20 0.52
PTPN2 P17706 1/20 0.52
PTPN1 P18031 1/20 0.52
PTPRB P23467 1/20 0.52
PTPRE P23469 1/20 0.52
TSHR P16473 2/20 0.49
MAPK10 P53779 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5449174 0.91 CFTR (0.55) KMT2ANOD1CFTRCNR2CNR1
SCHEMBL5453343 0.86 CFTR (0.54) KMT2ANOD1CFTRCNR2CNR1
SCHEMBL5459324 0.85 CFTR (0.55) KMT2ANOD1CFTRCNR2CNR1
SCHEMBL5449075 0.83 CFTR (0.66) KMT2ACFTRCNR2CNR1ALDH1A1
SCHEMBL8290653 0.81 CFTR (0.67) KMT2ACFTRCNR2ALDH1A1HSD17B10
SCHEMBL5445117 0.81 PTPRC (0.65) KMT2ACFTRCNR2CNR1ALDH1A1
SCHEMBL5460329 0.80 CFTR (0.62) KMT2ACFTRCNR2CNR1ALDH1A1
SCHEMBL5444948 0.79 FLT3 (0.70) KMT2ACFTRCNR2ALDH1A1HSD17B10
SCHEMBL5451324 0.78 CFTR (0.54) KMT2ACFTRCNR2CNR1ALDH1A1
SCHEMBL5449732 0.78 ALDH1A1 (0.73) CFTRCNR2CNR1ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 KMT2A 4785/4885NOD1 370/4885CFTR 2030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.